Tirzepatide is a dual GLP-1/GIP receptor agonist prescribed for physician supervised weight loss. Clinical trials show up to 22%* average body weight loss — among the highest demonstrated in published GLP-1 class research. Compounded tirzepatide is not FDA-approved.
Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. Unlike semaglutide, which targets only the GLP-1 receptor, tirzepatide activates both GLP-1 and GIP receptors simultaneously — producing more significant appetite suppression and metabolic improvement.
In the landmark SURMOUNT-1 clinical trial, patients on tirzepatide achieved an average of 22% body weight reduction — among the most substantial results published for this medication class in a major randomized controlled trial.
Compounded tirzepatide is prepared by our licensed, 503A and 503B registered pharmacy partners with physician-personalized dosing. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
The most clinically powerful GLP-1 program available. Physician supervised, pharmaceutical-grade, shipped nationwide.
Physician review required. Results vary. Compounded medications are not FDA-approved. Eligibility: BMI ≥30, or BMI ≥27 with qualifying comorbidity.